Comparing Beauty Health (SKIN) & Its Peers
3 min read
Beauty Health (NASDAQ:SKIN – Get Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Beauty Health to similar businesses based on the strength of its profitability, earnings, institutional ownership, risk, dividends, valuation and analyst recommendations.
Institutional and Insider Ownership
72.0% of Beauty Health shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 14.3% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Beauty Health and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Beauty Health | $260.09 million | -$375.11 million | -3.64 |
| Beauty Health Competitors | $1.15 billion | $84.54 million | -497.13 |
Beauty Health’s rivals have higher revenue and earnings than Beauty Health. Beauty Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and target prices for Beauty Health and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 0 | 1 | 9 | 0 | 2.90 |
| Beauty Health Competitors | 1272 | 4588 | 7991 | 221 | 2.51 |
Beauty Health currently has a consensus target price of $26.11, suggesting a potential upside of 111.08%. As a group, “Surgical & medical instruments” companies have a potential upside of 56.19%. Given Beauty Health’s stronger consensus rating and higher possible upside, analysts plainly believe Beauty Health is more favorable than its rivals.
Volatility & Risk
Beauty Health has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Beauty Health’s rivals have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.
Profitability
This table compares Beauty Health and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | -117.84% | -0.01% | N/A |
| Beauty Health Competitors | -748.46% | -64.82% | -19.49% |
Summary
Beauty Health beats its rivals on 8 of the 12 factors compared.
About Beauty Health (Get Rating)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer’s preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.
